ThinkstockThe saying is that if there is a trading strategy, then there is an ETF strategy for that as well. Now the markets are getting a new exchange-traded fund strategy aimed at…
ThinkstockThe drug and pharmaceutical sector is supposed to be a defensive one by nature, even if this week’s government shutdown and impending debt ceiling weighed heavily on biotech stocks. Credit Suisse’s Vamil…
ThinkstockWhen the markets go through periods of great gains, it is not uncommon to see companies start to take more radical efforts to increase their total return for shareholders. Some may go…
ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the population. From obesity to food allergies to prostate cancer, the top companies…
ThinkstockAs the pharmaceuticals industry looks toward restructuring and separation of undervalued assets, Jefferies analysts have prepared a highly proprietary sum of the parts analysis for their coverage universe to find the best…
ThinkstockOne of the downsides to a market that seems to go up every day is knowing what stocks to own or sell as the market chugs higher. One strategy for investors to…
ThinkstockAbbVie Inc. (NYSE: ABBV) reported first-quarter 2013 results before markets opened this morning. The pharmaceutical research firm posted adjusted diluted earnings per share (EPS) of $0.68 on revenues of $4.33 billion. Total…
U.S. equity markets opened higher this morning, but struggled to stay in positive territory for most of the morning. There was little economic data released today. In Asia, Hong Kong’s consumer price…
Investors and traders are on the lookout for fresh research ideas from Wall St. that will lead to higher income or more profits. 24/7 Wall St. reviews many fresh research calls each…
ThinkstockWith the markets making new highs seemingly every day, it is understandable that investors may be finding it harder and harder to find stocks that do not appear overvalued, or at a…
U.S. equity markets opened flat this morning, largely due to a slew of data from Europe that essentially cancelled any good news with an equal dollop of bad. U.S. unemployment data came…
ThinkstockHave some widely owned health care names hit a wall when it comes to growth and earnings? In a research report issued today, Credit Suisse Group Inc. (NYSE: CS) issues some not…
Jon OggThese are some of this Thursday’s top analyst upgrades, downgrades and initiations seen from Wall St. research calls. AbbVie Inc. (NYSE: ABBV) started as Neutral at Credit Suisse. Akamai Technologies Inc. (NASDAQ:…
Stocks have rallied sharply during January after the last-minute congressional compromise on the fiscal cliff. While the deal was far from perfect, it averted not only a disaster for the U.S. economy,…
ThinkstockAfter a strong year of relative performance for pharmaceutical stocks in 2012, the analysts at Jefferies Group Inc. (NYSE: JEF) predict that 2013 could show more of the same. However they are…
